Vista Wealth Management Group LLC cut its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 7.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,849 shares of the company’s stock after selling 605 shares during the period. Vista Wealth Management Group LLC’s holdings in Johnson & Johnson were worth $1,217,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Moneta Group Investment Advisors LLC boosted its holdings in shares of Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after purchasing an additional 54,326,454 shares during the last quarter. Norges Bank acquired a new stake in Johnson & Johnson during the fourth quarter worth approximately $4,609,399,000. Morgan Stanley raised its position in Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after buying an additional 4,521,062 shares during the last quarter. Nordwand Advisors LLC acquired a new stake in Johnson & Johnson during the 4th quarter valued at $785,273,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Johnson & Johnson by 15.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock worth $5,171,919,000 after acquiring an additional 3,849,148 shares in the last quarter. Institutional investors own 67.57% of the company’s stock.
Insider Activity at Johnson & Johnson
In other news, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the transaction, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The disclosure for this sale can be found here. In the last 90 days, insiders sold 47,163 shares of company stock valued at $7,928,856. Insiders own 0.20% of the company’s stock.
Wall Street Analyst Weigh In
View Our Latest Research Report on JNJ
Johnson & Johnson Price Performance
Shares of JNJ opened at $173.15 on Wednesday. The firm’s fifty day simple moving average is $163.47 and its 200-day simple moving average is $161.02. The firm has a market capitalization of $450.01 billion, a price-to-earnings ratio of 35.05, a PEG ratio of 2.90 and a beta of 0.54. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $181.04. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.62 by $0.18. The firm had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The firm’s revenue was up 6.3% compared to the same quarter last year. During the same period last year, the firm earned $2.59 EPS. Equities analysts forecast that Johnson & Johnson will post 10.75 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be issued a dividend of $1.19 per share. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.75%. Johnson & Johnson’s dividend payout ratio is currently 96.36%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- How to Invest in Virtual Reality
- 5 Best Fintech Stocks to Buy Now
- The How And Why of Investing in Oil Stocks
- UPS Slipping To More Attractive Levels On Weak OutlookÂ
- Market Cap Calculator: How to Calculate Market Cap
- More Good News Coming? GoodRx Spikes Ahead of Q2 Earnings
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
